Eris Lifesciences reports 44% revenue growth in FY25

** Eris Lifesciences (BSE: ERIS) announced strong financial results for the fiscal year 2025, marked by substantial revenue and profitability growth. Operating revenue reached INR 2,894 crore, a 44% increase year-over-year, while EBITDA soared to INR 1,017 crore, representing a 51% jump. Profit After Tax stood at INR 375 crore. The company also highlighted a cash conversion ratio of ~80% for the last 8 years and 105% in FY25 with superior cash conversion ratios in FY25 and strategic investments in R&D.